We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 21, 2018

Palbociclib ± the Endocrine Therapy Received Before Disease Progression for ER+/HER2− Metastatic Breast Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Palbociclib as Single Agent or in Combination With the Endocrine Therapy Received Before Disease Progression for Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: TREnd Trial
Ann. Oncol 2018 Jun 11;[EPub Ahead of Print], L Malorni, G Curigliano, AM Minisini, S Cinieri, CA Tondini, K D'Hollander, G Arpino, A Bernardo, A Martignetti, C Criscitiello, F Puglisi, M Pestrin, G Sanna, E Moretti, E Risi, C Biagioni, A McCartney, L Boni, M Buyse, I Migliaccio, L Biganzoli, A Di Leo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading